Although our sample size is relatively small, these findings indicate a potential association between the Arg/Arg and Ser/Arg genotypes of the CDKN1A c.93C > A polymorphism and the beneficial effect of bevacizumab in glioblastoma treatment. The gene discussed is CDKN1A; the disease is glioblastoma.